Complementemia in pregnancies with antiphospholipid syndrome

Antonio Lanzone, Sara De Carolis, Angela Botta, S. Tabacco, A. Giannini, C. Garufi, P. Benedetti Panici

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Prognosis of pregnancies in women with antiphospholipid syndrome has dramatically improved over the past two decades using conventional treatment with low molecular weight heparin and low-dose aspirin. However, despite this regimen, 10–15% of antiphospholipid syndrome patients experience pregnancy losses. Several studies have been performed in order to identify risk factors predictive of complications. Thrombosis has been generally accepted as the key pathogenetic mechanism underlying pregnancy morbidity. However, the thrombogenic state alone is not able to explain all the different mechanisms leading to pregnancy failure. In fact, emerging evidence shows that complement pathway could play an important role in mediating clinical events in antiphospholipid syndrome. However, the exact mechanism through which complement mediates antiphospholipid syndrome complications remains unknown. Low complement levels (C3 and C4) are associated with poor pregnancy outcome in women with antiphospholipid syndrome in different studies. Hypocomplementemia could be indicated as an early predictor of adverse pregnancy outcome, available at the beginning of pregnancy for starting, if necessary, additional treatment to conventional therapy. However, future studies need to better understand the impact of low complement level on antiphospholipid syndrome pregnancy outcome.
Original languageEnglish
Pages (from-to)1503-1509
Number of pages7
Publication statusPublished - 2019


  • Anticardiolipin antibodies
  • antiphospholipid syndrome
  • complement
  • complement activation
  • lupus anticoagulant
  • pregnancy


Dive into the research topics of 'Complementemia in pregnancies with antiphospholipid syndrome'. Together they form a unique fingerprint.

Cite this